UCB Aktie

 

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

BRUSSELS (dpa-AFX) - According to results from a multicenter study published by Neurology, UCB SA (UCBJY) showed on Monday, that its investigational pyrimidine nucleoside therapy has the potential......

Trotz Shutdown-Gefahr startet Wall Street freundlich: Dow +0,13 %, S&P 500 +0,27 %. Der Dollar steht unter Druck, Gold markiert Rekord. In Europa gemischt, der DAX schließt kaum bewegt bei 23.745 Punkten, -0,02 %. Im Fokus: Rheinmetall knackt intraday 2.000 Euro nach Munitionsauftrag über 444 Mio. Euro. Rüstungswerte generell fest. Lufthansa bestätigt den Abbau von 4.000 Verwaltungsstellen und hebt die Zielmarge für das bereinigte EBIT auf 8-10 % an; 2024 lag das bereinigte EBIT bei 1,6 Mrd. Euro. Klöckner & Co. verkauft acht US-Distributionsstandorte, fokussiert auf höherwertiges und Service-Center-Geschäft. IPO-News: Ottobock setzt die Preisspanne auf 62–66 Euro (Bewertung 4,0-4,2 Mrd. Euro ), Ersthandel geplant am 09.10.2025. Biotech-Schock: MoonLake crasht um fast 90 % nach Studiendaten; UCB springt zweistellig. Nach Cyberangriff fährt Jaguar Land Rover die Produktion schrittweise hoch, flankiert von einer Kreditgarantie über 1,5 Mrd. Pfund. Börsenweisheit zum Schluss: "Die Märkte könn...

UCB SA shares surged to a record high after analysts said late-stage clinical trial data from rival MoonLake Immunotherapeutics showed UCB's skin disorder medicine is superior. MoonLake lost most of its value in premarket trading....

So etwas sieht man selten: Die Aktie des belgischen Pharma-Riesen UCB schießt zum Start in die neue Handelswoche um 16 Prozent in die Höhe. Dabei ist es nicht das Unternehmen selbst, was für den massiven Kursschub sorgt, der für ein Plus bei der Marktkapitalisierung von etwa sieben Milliarden Euro verantwortlich ist....

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

GREENVILLE, S.C., Sept. 26, 2025 (GLOBE NEWSWIRE) -- United Community Banks, Inc. (NYSE: UCB) announces it will release its third quarter 2025 financial results on Wednesday, October 22, 2025, before the stock market opens. The company also will hold a conference call at 9:00 a.m. EST on Wednesday, October 22, 2025, to discuss its financial results, business highlights, and outlook....

The Interleukin-13 inhibitors market is witnessing robust growth, driven by the rising prevalence of atopic dermatitis, asthma, and other type 2 inflammatory diseases. Additionally, the expected launch of therapies such as ASLAN Pharmaceuticals' Eblasakimab, UCB Pharma's Galvokimig, and......

BRUSSELS (dpa-AFX) - UCB SA (UCBJY), Wednesday announced has released three-year results from its BE HEARD trials demonstrating that BIMZELX or bimekizumab-bkzx, the first and only approved therap......

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does United Community Banks (UCB) have what it takes? Let's find out....

The next leg of a huge share-price rally for Belgium's UCB SA — driven by the success of its Bimzelx skin disease medicine — hinges on key results for a rival drug....

Dr. Richard Fahrner and Dr. Tamara Agajanov add expertise in accelerated approvalsCAMBRIDGE, Mass.--(BUSINESS WIRE)--$HIND--Vyome Holdings, Inc. (NASDAQ: HIND), a clinical-stage healthcare holding company, today announced the appointment of Dr. Richard Fahrner as Chief Technology Officer and Dr. Tamara Agajanov, MD, as Senior Vice President – Clinical Development. Dr. Fahrner brings to Vyome over 25 years of experience in drug development, recently serving as the head of pharmaceutical development at Ra Pharmaceuticals, which was acquired by UCB in a $2.5B deal. He also served as a research and development leader at Catabasis, Pfizer, Sanofi and Gilead. Dr. Fahrner has been involved with the development of more than 17 approved medicines, including Vpriv and Elaprase, which were granted accelerated approvals by the U.S. Food and Drug Administration (USFDA). Dr. Fahrner received his PhD in Biochemistry and Molecular Biology from UCLA. Dr. Agajanov brings nearly 30 years of experience in clinical operatio...

Das Instrument UNC BE0003739530 UCB S.A. EQUITY hat seinen ersten Handelstag am 05.09.2025: CONTINUOUS TRADING WITH AUCTIONS, PAG LUX0, SettlCurr EUR, CCP Y The instrument UNC BE0003739530 UCB S.A. EQUITY has its first trading date on 05.09.2025: CONTINUOUS TRADING WITH AUCTIONS, PAG LUX0, SettlCurr EUR, CCP Y...

Seasoned executive with three decades of experience in pharma and biotech Biotech board experience from Cytovation ASA, Antev Ltd, and Calliditas Therapeutics, and governance / senior leadership experience from UCB, Novartis and Schering-Plough (now Merck) Appointment comes as Blue Cell......

26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies Data include an open-label extension study describing the long-term safety of FINTEPLA®▼ (fenfluramine)[1] and global functioning in......

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does United Community Banks (UCB) have what it takes? Let's find out....

United Community Banks (UCB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy)....

UCB (UCBJY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy)....

Dividend hikes from CHMG, MTB, MLM and UCB stand out as investors seek stability amid Fed rate-cut uncertainty and market volatility....

MTB, CHMG and UCB hike dividends this week, signaling strength amid market volatility....